Skip to main content

Advertisement

SpringerLink
Log in

An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Despite its limitations, in part due to decreased specificity in advanced disease, serum lactate dehydrogenase (LDH) is one of few serum factors used in cancer staging. This study quantifies the predictive capabilities of LDH in stage IV melanoma of the skin and explores the validity of suggested demographic discrepancies which may exist in its use. The 1975–2017 Surveillance Epidemiology and End Results (SEER) database was queried for stage IV cutaneous melanoma cases. Demographic characteristics were compared between LDH groups using chi-square and t tests. Subsequent Cox multivariable regression was performed to assess survival differences. 334 cases of stage IV cutaneous melanoma (average age: 63.0 years) with measured serum LDH levels were identified. Of these patients, 150 (44.9%) had normal LDH, 112 (33.5%) had LDH < 1.5 × upper limit of normal (ULN), 57 (17.1%) had LDH 1.5–10 × ULN, and 15 (4.5%) had LDH > 10 × ULN. Lower incomes were associated with higher LDH; individuals with incomes < $50,000 had the greatest proportion of LDH 10 × ULN (19.2%; p = 0.0031). LDH > 10 × ULN also had the lowest proportion of White patients (p = 0.04). On Cox multivariable survival analysis, increasing LDH levels showed increased risk of death (LDH < 1.5 × ULN: HR = 2.05, p = 0.01; LDH 1.5–10 × ULN: HR = 1.46, p < 0.001; LDH > 10 × ULN: HR = 5.91, p < 0.001). This study reaffirms the utility of LDH as a significant predictor of mortality with incremental severity, suggesting possible use for mortality projections. We note that Black patients and those with lower incomes may be more likely to have an elevated LDH. Older age groups and presence of ulceration among patients with stage IV melanoma were also associated with a greater risk of mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Atkinson V (2017) Recent advances in malignant melanoma. Intern Med J 47(10):1114–1121. https://doi.org/10.1111/imj.13574

    Article  PubMed  Google Scholar 

  2. Five-Year Survival Rates | SEER Training. https://training.seer.cancer.gov/melanoma/intro/survival.html. Accessed 13 July 2021

  3. Guy GP, Ekwueme DU, Tangka FK, Richardson LC (2012) Melanoma treatment costs. Am J Prev Med 43(5):537–545. https://doi.org/10.1016/j.amepre.2012.07.031

    Article  PubMed  PubMed Central  Google Scholar 

  4. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC (2010) Economic burden of melanoma in the elderly population: population-based analysis of the surveillance, epidemiology, and end results (SEER)–Medicare Data. Arch Dermatol 146(3):249–256. https://doi.org/10.1001/archdermatol.2009.389

    Article  PubMed  Google Scholar 

  5. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL (2004) Contemporary surgical treatment of advanced-stage melanoma. Arch Surg Chic Ill 1960. 139(9):961–966. https://doi.org/10.1001/archsurg.139.9.961 (discussion 966-967)

    Article  Google Scholar 

  6. Balch CM, Gershenwald JE, jaw SS et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. https://doi.org/10.1200/JCO.2009.23.4799

    Article  PubMed  PubMed Central  Google Scholar 

  7. Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A (2010) Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. Anticancer Res 30(5):1799–1805

    CAS  PubMed  Google Scholar 

  8. Belter B, Haase-Kohn C, Pietzsch J (2017) Biomarkers in malignant melanoma: recent trends and critical perspective. In: Ward WH, Farma JM (eds) Cutaneous melanoma: etiology and therapy. Codon Publications. http://www.ncbi.nlm.nih.gov/books/NBK481856/. Accessed 25 July 2022

  9. Petrelli F, Cabiddu M, Coinu A et al (2015) Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 54(7):961–970. https://doi.org/10.3109/0284186X.2015.1043026

    Article  CAS  PubMed  Google Scholar 

  10. Stark MS, Klein K, Weide B et al (2015) The prognostic and predictive value of melanoma-related MicroRNAs using tissue and serum: a MicroRNA Expression Analysis. EBioMedicine 2(7):671–680. https://doi.org/10.1016/j.ebiom.2015.05.011

    Article  PubMed  PubMed Central  Google Scholar 

  11. Fischer GM, Carapeto FCL, Joon AY et al (2020) Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med 9(22):8650–8661. https://doi.org/10.1002/cam4.3474

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xu J, Zhao J, Wang J, Sun C, Zhu X (2021) Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy. Medicine (Baltimore) 100(14):e25318. https://doi.org/10.1097/MD.0000000000025318

    Article  CAS  PubMed  Google Scholar 

  13. Cancer Statistics (2021) Siegel. CA Cancer J Clin. https://doi.org/10.3322/caac.21654 (Accessed September 20, 2021)

    Article  Google Scholar 

  14. Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS (2000) Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer 88(3):589–595

    Article  CAS  PubMed  Google Scholar 

  15. Osborne JE, Hutchinson PE (2001) Clinical correlates of Breslow thickness of malignant melanoma. Br J Dermatol 144(3):476–483. https://doi.org/10.1046/j.1365-2133.2001.04071.x

    Article  CAS  PubMed  Google Scholar 

  16. Scott JF, Conic RZ, Thompson CL, Gerstenblith MR, Bordeaux JS (2018) Stage IV melanoma of unknown primary: a population-based study in the United States from 1973 to 2014. J Am Acad Dermatol 79(2):258-265.e4. https://doi.org/10.1016/j.jaad.2018.03.021

    Article  PubMed  PubMed Central  Google Scholar 

  17. Xing Y, Chang GJ, Hu CY et al (2010) Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 116(9):2234–2241. https://doi.org/10.1002/cncr.24966

    Article  PubMed  Google Scholar 

  18. Dawes SM, Tsai S, Gittleman H, Barnholtz-Sloan JS, Bordeaux JS (2016) Racial disparities in melanoma survival. J Am Acad Dermatol 75(5):983–991. https://doi.org/10.1016/j.jaad.2016.06.006

    Article  PubMed  Google Scholar 

  19. Cormier JN, Xing Y, Ding M et al (2006) Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 166(17):1907. https://doi.org/10.1001/archinte.166.17.1907

    Article  PubMed  Google Scholar 

  20. Kaminska-Winciorek G, Calik J, Wydmanski J, Schwartz RA, Czajkowski R (2014) Primary melanoma in rare locations: clinical and dermatoscopic features. Indian J Dermatol Venereol Leprol 80(4):369–371. https://doi.org/10.4103/0378-6323.136976

    Article  PubMed  Google Scholar 

  21. Patel GA, Ragi G, Krysicki J, Schwartz RA (2008) Subungual melanoma: a deceptive disorder. Acta Dermatovenerol Croat ADC 16(4):236–242

    PubMed  Google Scholar 

  22. Wang Y, Zhao Y, Ma S (2016) Racial differences in six major subtypes of melanoma: descriptive epidemiology. BMC Cancer 16(1):691. https://doi.org/10.1186/s12885-016-2747-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Elias ML, John AM, Maddukuri S, Schwartz RA, Lambert WC (2021) Treatment delay in melanoma: a risk factor analysis of an impending crisis. Cutis 107(4):E19–E26. https://doi.org/10.12788/cutis.0235

    Article  PubMed  Google Scholar 

  24. Collins KK, Fields RC, Baptiste D, Liu Y, Moley J, Jeffe DB (2011) Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol 18(10):2925–2936. https://doi.org/10.1245/s10434-011-1706-3

    Article  PubMed  PubMed Central  Google Scholar 

  25. Mokwatsi GG, Schutte AE, Kruger R (2016) A biomarker of tissue damage, lactate dehydrogenase, is associated with fibulin-1 and oxidative stress in blacks: the SAfrEIC study. Biomarkers 21(1):48–55. https://doi.org/10.3109/1354750X.2015.1118532

    Article  CAS  PubMed  Google Scholar 

  26. Rouhani P, Hu S, Kirsner RS (2008) Melanoma in hispanic and black Americans. Cancer Control J Moffitt Cancer Cent 15(3):248–253. https://doi.org/10.1177/107327480801500308

    Article  Google Scholar 

  27. Byrd-Miles K, Toombs EL, Peck GL (2007) Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians. J Drugs Dermatol JDD 6(1):10–16

    PubMed  Google Scholar 

  28. Culp MB (2019) 29 Melanoma among non-hispanic black Americans. Prev Chronic Dis. https://doi.org/10.5888/pcd16.180640

    Article  PubMed  PubMed Central  Google Scholar 

  29. Elias ML, Behbahani S, Maddukuri S, John AM, Schwartz RA, Lambert WC (2019) Prolonged overall survival following metastasectomy in stage IV melanoma. J Eur Acad Dermatol Venereol JEADV 33(9):1719–1725. https://doi.org/10.1111/jdv.15667

    Article  CAS  PubMed  Google Scholar 

  30. Ward-Peterson M, Acuña JM, Alkhalifah MK et al (2016) Association between race/ethnicity and survival of melanoma patients in the united states over 3 decades. Medicine (Baltimore) 95(17):e3315. https://doi.org/10.1097/MD.0000000000003315

    Article  PubMed  Google Scholar 

  31. Myles ZM, Buchanan N, King JB et al (2012) Anatomic distribution of malignant melanoma on the non-Hispanic black patient, 1998–2007. Arch Dermatol 148(7):797–801. https://doi.org/10.1001/archdermatol.2011.3227

    Article  PubMed  Google Scholar 

  32. Zell JA, Cinar P, Mobasher M, Ziogas A, Meyskens FL, Anton-Culver H (2008) Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol Off J Am Soc Clin Oncol 26(1):66–75. https://doi.org/10.1200/JCO.2007.12.3604

    Article  Google Scholar 

  33. Pollitt RA, Clarke CA, Shema SJ, Swetter SM (2008) California medicaid enrollment and melanoma stage at diagnosis. Am J Prev Med 35(1):7–13. https://doi.org/10.1016/j.amepre.2008.03.026

    Article  PubMed  PubMed Central  Google Scholar 

  34. Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY (2008) Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 9(3):222–231. https://doi.org/10.1016/S1470-2045(08)70032-9

    Article  PubMed  Google Scholar 

  35. Petrelli F, Ardito R, Merelli B et al (2019) Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Melanoma Res 29(1):1–12. https://doi.org/10.1097/CMR.0000000000000520

    Article  CAS  PubMed  Google Scholar 

  36. Deckers EA, Kruijff S, Brouwers AH et al (2020) The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 46(11):2147–2153. https://doi.org/10.1016/j.ejso.2020.07.011

    Article  CAS  Google Scholar 

  37. Zhang J, Yao YH, Li BG, Yang Q, Zhang PY, Wang HT (2015) Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep 5:9800. https://doi.org/10.1038/srep09800

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. 37 Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor|Dermatology|JAMA Dermatology|JAMA Network. https://jamanetwork.com/journals/jamadermatology/fullarticle/2731995. Accessed 13 July 2021

  39. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA (1980) The prognostic significance of ulceration of cutaneous melanoma. Cancer 45(12):3012–3017. https://doi.org/10.1002/1097-0142(19800615)45:12%3c3012::aid-cncr2820451223%3e3.0.co;2-o

    Article  CAS  PubMed  Google Scholar 

  40. Hout in’t FEM, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, Scolyer RA (2012) Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann Surg 255(6):1165–1170. https://doi.org/10.1097/SLA.0b013e31824c4b0b

    Article  Google Scholar 

  41. Bønnelykke-Behrndtz ML, Schmidt H, Christensen IJ et al (2014) Prognostic stratification of ulcerated melanoma: not only the extent matters. Am J Clin Pathol 142(6):845–856. https://doi.org/10.1309/AJCPW56PHGLFTKZC

    Article  PubMed  Google Scholar 

  42. Sirott MN, Bajorin DF, Wong GY et al (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10):3091–3098. https://doi.org/10.1002/1097-0142(19931115)72:10%3c3091::aid-cncr2820721034%3e3.0.co;2-v

    Article  CAS  PubMed  Google Scholar 

  43. Nieder C, Marienhagen K, Dalhaug A, Norum J (2012) Towards improved prognostic scores predicting survival in patients with brain metastases: a pilot study of serum lactate dehydrogenase levels. Sci World J. https://doi.org/10.1100/2012/609323

    Article  Google Scholar 

  44. Weide B, Elsässer M, Büttner P et al (2012) Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107(3):422–428. https://doi.org/10.1038/bjc.2012.306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Balch CM, jaw SS, Gershenwald JE et al (2013) Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 20(12):3961–3968. https://doi.org/10.1245/s10434-013-3100-9

    Article  PubMed  PubMed Central  Google Scholar 

  46. Shen W, Sakamoto N, Yang L (2016) Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis. BMC Cancer 16(1):413. https://doi.org/10.1186/s12885-016-2438-3

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lideikaitė A, Mozūraitienė J, Letautienė S (2017) Analysis of prognostic factors for melanoma patients. Acta Med Litu 24(1):25–34. https://doi.org/10.6001/actamedica.v24i1.3460

    Article  PubMed  PubMed Central  Google Scholar 

  48. Chao C, Martin RCG, Ross MI et al (2004) Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 11(3):259–264. https://doi.org/10.1245/ASO.2004.04.015

    Article  PubMed  Google Scholar 

  49. Lasithiotakis K, Leiter U, Meier F et al (2008) Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 112(8):1795–1804. https://doi.org/10.1002/cncr.23359

    Article  PubMed  Google Scholar 

  50. Weiss SA, Han J, Darvishian F et al (2016) Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. J Transl Med 14(1):299. https://doi.org/10.1186/s12967-016-1026-2

    Article  PubMed  PubMed Central  Google Scholar 

  51. Enninga EAL, Moser JC, Weaver AL et al (2017) Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med 6(10):2203–2212. https://doi.org/10.1002/cam4.1152

    Article  PubMed  PubMed Central  Google Scholar 

  52. Cockburn M, Swetter SM, Peng D, Keegan THM, Deapen D, Clarke CA (2008) Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol 59(6):1081–1085. https://doi.org/10.1016/j.jaad.2008.08.007

    Article  PubMed  PubMed Central  Google Scholar 

  53. Mahendraraj K, Sidhu K, Lau CSM, McRoy GJ, Chamberlain RS, Smith FO (2017) Malignant melanoma in African-Americans. Medicine (Baltimore) 96(15):e6258. https://doi.org/10.1097/MD.0000000000006258

    Article  PubMed  Google Scholar 

  54. Brady J, Kashlan R, Ruterbusch J, Farshchian M, Moossavi M (2021) Racial disparities in patients with melanoma: a multivariate survival analysis. Clin Cosmet Investig Dermatol 14:547–550. https://doi.org/10.2147/CCID.S311694

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Author notes

  1. Amar D. Desai and Sree Chinta contributed equally.

Authors and Affiliations

  1. Rutgers New Jersey Medical School, 185 South Orange Avenue, Newark, NJ, 07103, USA

    Amar D. Desai, Sree Chinta, Christopher Yeh, Vraj P. Shah, Boris Paskhover & Robert A. Schwartz

  2. Rutgers Robert Wood Johnson Medical School, Somerset, NJ, USA

    Radhika Shah

Authors
  1. Amar D. Desai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sree Chinta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vraj P. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Radhika Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Boris Paskhover
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert A. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AD and SC wrote the main manuscript text. CY and VS contributed to statistical analysis. RS, BP, and RS aided with idea curation and manuscript editing.

Corresponding author

Correspondence to Robert A. Schwartz.

Ethics declarations

Conflict of interest

AD, SC, CY, VS, RS, BP, and RS all declare they have no conflicts of interest to report.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Desai, A.D., Chinta, S., Yeh, C. et al. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability. Arch Dermatol Res 315, 799–806 (2023). https://doi.org/10.1007/s00403-022-02425-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-022-02425-0

Keywords

Search

Navigation